Document Detail

A single-institution, 20-year prospective experience with an affordable Fc-receptor blockade method to treat patients with chronic, refractory autoimmune thrombocytopenic purpura.
MedLine Citation:
PMID:  18402333     Owner:  NLM     Status:  MEDLINE    
In a 20-year period in a single institution, 34 patients with chronic, refractory autoimmune thrombocytopenic purpura were prospectively treated with ex vivo anti-D opsonized autologous red blood cells. All patients had received previous treatment with steroids and/or immunosuppressive agents, and 11 had been splenectomized. Twenty one patients had an increase in the platelet count; in five cases, the increase was more than 50 x 10(9)/L platelets and in 16 the increase was more than 100 x 10(9)/L platelets. Early responses were observed in 20 patients and late responses in seven, whereas seven patients (20%) did not respond at all. Nine of the 20 individuals who achieved an ER had a subsequent drop in the platelet count; however, only three had a drop below 50 x 10(9)/L. When last censored, of the 34 patients, 24 (70%) had a platelet count above 50 x 10(9)/L. The 84-month thrombocytopenia-free (over 50 x 10(9)/L platelets) status of the whole group is 70%, whereas the 84-month complete remission (over 100 x 10(9)/L platelets) status of the whole group is 50%. It is concluded that the use of ex vivo anti-D opsonized red blood cells may represent another, substantially cheaper treatment of patients with chronic, refractory, autoimmune thrombocytopenic purpura.
Roberto Estrada-Gómez; Olga Vargas-Castro; Mabel Oropeza-Borges; Martha L González-Carrillo; Beatriz Pérez-Romano; Guillermo J Ruiz-Argüelles
Related Documents :
20950403 - Autologous 111 in-labelled platelet sequestration studies in patients with primary immu...
2191323 - Chronic itp as a model for immunization by platelets.
9662163 - Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under ...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición     Volume:  59     ISSN:  0034-8376     ISO Abbreviation:  Rev. Invest. Clin.     Publication Date:    2007 Nov-Dec
Date Detail:
Created Date:  2008-04-11     Completed Date:  2008-06-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421552     Medline TA:  Rev Invest Clin     Country:  Mexico    
Other Details:
Languages:  eng     Pagination:  424-7     Citation Subset:  IM    
Laboratorios Clinicos de Puebla.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Child, Preschool
Combined Modality Therapy / economics
Drug Costs
Drug Resistance
Erythrocyte Transfusion*
Immunosuppression / economics,  methods*
Immunosuppressive Agents / therapeutic use
Isoantibodies / therapeutic use*
Middle Aged
Opsonin Proteins / therapeutic use*
Platelet Count
Prospective Studies
Purpura, Thrombocytopenic, Idiopathic / drug therapy*,  immunology,  surgery
Receptors, IgG / antagonists & inhibitors*
Remission Induction
Rh-Hr Blood-Group System / immunology
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Isoantibodies; 0/Opsonin Proteins; 0/RHO(D) antibody; 0/Receptors, IgG; 0/Rh-Hr Blood-Group System; 0/Rho(D) antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Endoscopic treatment of high-risk bleeding ulcers: success, rebleeding and mortality.
Next Document:  Quality of medication prescribing for elderly patients with non-malignant pain syndrome attending fa...